Dendreon reports $2.09 million of income from operations for April

By Caroline Salls

Pittsburgh, May 21 – Dendreon Corp. posted $2.09 million of income from operations for April on $3.36 million in total revenue, according to its monthly operating report filed Thursday with the Securities and Exchange Commission.

Those figures showed improvement over the $316,000 loss from operations reported for March on $226,000 of total revenue.

The net loss for April was $728,000, narrowing from a $6.4 million March net loss.

The company also reported $456.26 million in cash and cash equivalents as of April 30, down from $458.79 million at the end of March.

Dendreon, a Seattle-based biotechnology company that focuses on novel therapeutics to enhance cancer treatment options, filed for bankruptcy on Nov. 10, 2014. The Chapter 11 case number is 14-12515.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.